Researchers underscore the importance of personalized medicine in patients with metabolic liver disease


Researchers at the CIBER for Liver and Digestive Diseases (CIBEREHD) have discovered, after five years of monitoring patients with metabolic liver disease, the importance of personalized medicine.

The national and multicenter study, published in the journal ‘Liver International’, has been led by Javier Ampuero and Manuel Romero Gómez, heads of the SeLiver group, belonging to the Area of ​​liver, digestive and inflammatory diseases of the Institute of Biomedicine of Seville and doctors of the Virgen del Rocío University Hospital.

The study has been developed in the environment of the HEPAmet Registry, and included almost 2,000 patients with a histological diagnosis of metabolic hepatic steatosis (EHmet) and it has been described that the histological characteristics that define steatohepatitis decrease in the presence of advanced liver disease.

“Our findings show that there are patients who are not included in clinical trials and therefore do not receive a therapy that could benefit them, because, despite continuing to have liver disease, they have lost some common histological element in the diagnosis” , concludes Ampuero.

Furthermore, those patients with steatohepatitis with and without inflammatory activity presented clinical characteristics and a very similar prognosis, with rates of progression to cirrhosis higher than those patients with simple steatosis.

This collaborative project, carried out between more than 30 Spanish hospitals and 13 researchers belonging to CIBEREHD groups, highlights the importance of personalized medicine and individual evaluation of patients prior to their inclusion in experimental therapies.

Nonalcoholic fatty liver disease, recently renamed metabolic hepatic steatosis (MetHE), is one of the most prevalent liver diseases worldwide, and is currently the third indication for liver transplantation.

Diagnosis is made by liver biopsy, and patients are classified as simple steatosis, initially benign, and non-alcoholic steatohepatitis (NASH), presenting a
inflammatory component and can be associated with different states of fibrosis that can lead to cirrhosis and liver cancer.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.